信立泰SAL0137药品临床试验申请获受理

Core Viewpoint - The company, Xinlitai (002294.SZ), has received an acceptance notice from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein(a) levels [1] Group 1 - The clinical trial application for SAL0137 has been accepted, indicating progress in the drug development process [1] - SAL0137 is a proprietary oral small molecule drug developed by the company [1] - The application specifically targets the treatment of elevated lipoprotein(a), a significant health concern [1]